API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. ST /
  3. ATORX.ST

Alligator Bioscience AB (ATORX ST) stock market data APIs

kr0.882 0.33(59.6%) as of November 21, 2024
Price chart is built with Anychart

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company's product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, an immunostimulatory antibody, which is in phase 1 clinical trial for the treatment of metastatic cancer. In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; MacroGenics, Inc.; Biotheus Inc.; BioArctic AB; and Abclon Inc. The company was founded in 2000 and is headquartered in Lund, Sweden.

Alligator Bioscience AB Financial Data Overview

0.954
0.882
-
1.05
0.8
0.405-1.568
401 M
758 M
27 774 K
-0.0877
1.48
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ATORX',
Type: 'Common Stock',
Name: 'Alligator Bioscience AB',
Exchange: 'ST',
CurrencyCode: 'SEK',
CurrencyName: 'Swedish krone',
CurrencySymbol: 'kr',
CountryName: 'Sweden',
CountryISO: 'SE',
OpenFigi: NULL,
ISIN: 'SE0000767188',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Alligator Bioscience AB Fundamental Data is available in our Financial Data APIs

  • Net Revenue 27 774 K
  • EBITDA -239 715 008
  • Earnings Per Share -0.35
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Alligator Bioscience AB Earnings via APIs

  • Latest Release 2024-10-24
  • EPS/Forecast NaN

Get Alligator Bioscience AB End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Alligator Bioscience AB latest news via APIs

Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty

LUND, Sweden, Jan. 19, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the initiation a sponsored research collaboration to study biomarker data from Alligator's OP...
  • ALLIGATOR
  • BEATTY
  • BIOSCIENCE
  • GREGORY BEATTY
  • NASDAQ STOCKHOLM
  • UNIVERSITY OF PENNSYLVANIA

Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported

LUND, Sweden, Jan. 18, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going OPTIMIZE-1 clinical Phase Ib/II trial with the company's lead asset...
  • ALLIGATOR
  • BIOSCIENCE
  • CLINICAL PHASE
  • LUND
  • NASDAQ STOCKHOLM
  • SWEDEN
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com